Hypocalcaemia in autoimmune haemolytic anaemia and pernicious anaemia

A.A. Baba and D. Maharaj

Royal Infirmary, Glasgow G4 OSF, UK.

Summary: A 71 year old woman presented with hypocalcaemia in association with autoimmune haemolytic anaemia and pernicious anaemia. The hypocalcaemia resolved only when the haemolytic anaemia and pernicious anaemia were successfully treated. The possible pathogenic mechanisms are discussed.

Introduction

Electrolyte and metabolic abnormalities including hypocalcaemia are recognized complications of haematological malignancies especially during treatment. It is not generally appreciated that similar abnormalities may occur in benign haematological conditions. Hypocalcaemia associated with pernicious anaemia has been reported previously.

This is the first report of the occurrence of unexplained hypocalcaemia in a patient with autoimmune anaemia and pernicious anaemia.

Case report

A 71 year old woman presented in June 1985 with a three month history of general malaise and weakness. Examination showed a well-hydrated woman who had marked pallor and mildly icteric sclerae. A goitre was palpable but the patient was clinically euthyroid and Chvostek’s and Trousseau’s signs were negative.

Investigations showed: haemoglobin 5.5 g/dl, white blood count 10.5 x 10^9/l, platelet count 275 x 10^9/l, mean cell volume 121 fl, mean cell haemoglobin 37 pg and 18% reticulocytes. Peripheral blood film showed oval macrocytosis, microspherocytes, polychromasia and hypersegmented neutrophils. Serum B₄, was reduced at 88 pg/ml while serum and red cell folate levels were normal. A Schilling test with intrinsic factor confirmed a diagnosis of pernicious anaemia. The direct antiglobulin test was strongly positive with IgG and C3d coating. Haptoglobin concentration was less than 0.15 g/dl (normal 0.26–5.0 g/dl). Sternal marrow aspirate showed a hypercellular marrow with megaloblastic erythropoiesis.

Biochemical investigations were as follows: normal serum electrolytes, urea 5.9 mmol/l, creatinine 110 μmol/l, direct bilirubin 25 μmol/l, serum calcium 1.4 mmol/l, phosphate 1.8 mmol/l. Serum magnesium, alkaline phosphatase transaminases and albumin level were all normal. Serum parathyroid hormone (PTH) levels ranged from 460 to 550 ng/ml (normal: <600 ng/ml), calcitonin 20 ng/l (normal 10–45 g/l), 25-hydroxycholecalciferol 44 nmol/l (normal 15–100 nmol/l) and 1,25-dihydroxycholecalciferol was 88 pmol/l (normal 20–120 pmol/l). Thyroid function tests revealed a sick euthyroid pattern with normal thyroxine and thyroid stimulating hormone levels but low triiodothyronine at 0.6 nmol/l (normal 0.9–2.8 nmol/l).

Tests for parietal cell, intrinsic factor, thyroid and parathyroid antibodies were negative. Isotope thyroid scan showed a multinodular goitre.

The patient was treated with prednisolone 60 mg/day. After 3 weeks of therapy there was no reduction in haemolysis and azathioprine 150 mg/day was added. Hydroxocobalamin was given with folate supplements during the period of haemolysis.

Hypocalcaemia was treated with oral calcium gluconate and 1α-hydroxycholecalciferol 1 μg/day. After 8 weeks of therapy the haemoglobin concentration had risen to 11.5 g/dl with reticulocytes and biochemical abnormalities had corrected with serum calcium 2.16 mmol/l and phosphate at 0.90 mmol/l.

Correspondence: D. Maharaj, M.R.C.P.(UK), M.R.C.Path., Department of Haematology, Memorial Hospital, Darlington DL3 6HX, UK.

Accepted: 25 June 1987

© The Fellowship of Postgraduate Medicine, 1988
Calcium supplements and 1α-hydroxycholecalciferol were stopped and the patient was discharged on prednisolone 10 mg/day and azathioprine 150 mg/day. Steroid therapy was later withdrawn and during 9 months of follow-up she has remained in haematological remission with normal biochemical indices on azathioprine alone.

Discussion

The exact cause of the transient hypocalcaemia in our patient is uncertain. There was no clinical or biochemical evidence of malabsorption. Hypomagnesaemia can lead to hypocalcaemia both by inhibiting secretion of PTH and impairing end organ response to PTH but these mechanisms were excluded as repeated magnesium levels were normal.

Hypergastrinaemia, a feature of pernicious anaemia may also lead to hypocalcaemia by stimulating calcitonin secretion which then suppresses mobilisation of calcium from bone. The increased level of gastrin in patients with pernicious anaemia is not, however, high enough to affect secretion of calcitonin. The calcitonin level in our patient was normal.

The occurrence of hypocalcaemia and hyperphosphataemia in the absence of significant renal impairment is classically thought to be diagnostic of hypoparathyroidism or pseudohypoparathyroidism. The PTH levels in our patient were normal though it could be argued that she had relative hypoparathyroidism with inappropriately low parathormone for the prevailing serum calcium concentration. An autoimmune aetiology could explain the hypoparathyroidism, the pernicious anaemia and the autoimmune haemolytic anaemia and appears to be the most likely explanation for the hypocalcaemia in our patient. Control of the autoimmune process with steroids and azathioprine may explain the return of the calcium level to normal.

Although the exact mechanism of the transient hypocalcaemia in autoimmune haemolytic anaemia and pernicious anaemia is uncertain, clinicians should be aware of this association so that appropriate therapeutic intervention can be taken to prevent morbidity from significant hypocalcaemia.

References

Hypocalcaemia in autoimmune haemolytic anaemia and pernicious anaemia.
A. A. Baba and D. Maharaj

doi: 10.1136/pgmj.64.747.61

Updated information and services can be found at:
http://pmj.bmj.com/content/64/747/61

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/